Clinical Trial Results:
PHARMACOKINETICS OF MICAFUNGIN DURING CONTINUOUS VENOVENOUS HEMOFILTRATION
Summary
|
|
EudraCT number |
2012-000904-14 |
Trial protocol |
AT |
Global end of trial date |
01 Jun 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 May 2020
|
First version publication date |
29 May 2020
|
Other versions |
|
Summary report(s) |
Synopsis |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MICA_HDF
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Medical University of Vienna
|
||
Sponsor organisation address |
Spitalgasse 23, Vienna, Austria, 1090
|
||
Public contact |
Florian Thalhammer, Medizinische Universität Wien, 0043 14040044400, florian.thalhammer@meduniwien.ac.at
|
||
Scientific contact |
Florian Thalhammer, Medizinische Universität Wien, 0043 14040044400, florian.thalhammer@meduniwien.ac.at
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Jun 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
18 Jun 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Jun 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Measuring pharmakokinetecs of micafungin during continuous renal replacement therapy
|
||
Protection of trial subjects |
None necessary (PK sampling using HF machine ports only)
|
||
Background therapy |
none | ||
Evidence for comparator |
no comparator | ||
Actual start date of recruitment |
27 Jul 2012
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 10
|
||
Worldwide total number of subjects |
10
|
||
EEA total number of subjects |
10
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
9
|
||
From 65 to 84 years |
1
|
||
85 years and over |
0
|
|
|||||||||||||
Recruitment
|
|||||||||||||
Recruitment details |
Recruitment started End of June 2013 and concluded December 2014. Patients from all ICUs of the general hospital of vienna were included. | ||||||||||||
Pre-assignment
|
|||||||||||||
Screening details |
Patients receiving Micafungin and high-flow CVVHDF or CVVHD during their ICU stay were screened. | ||||||||||||
Period 1
|
|||||||||||||
Period 1 title |
overall trial (overall period)
|
||||||||||||
Is this the baseline period? |
Yes | ||||||||||||
Allocation method |
Not applicable
|
||||||||||||
Blinding used |
Not blinded | ||||||||||||
Blinding implementation details |
none
|
||||||||||||
Arms
|
|||||||||||||
Arm title
|
Micafungin therapy | ||||||||||||
Arm description |
PK Parameters from Patients receiving Micafungin were evaluated | ||||||||||||
Arm type |
Experimental | ||||||||||||
Investigational medicinal product name |
Micafungin
|
||||||||||||
Investigational medicinal product code |
J02AX05
|
||||||||||||
Other name |
Mycamine
|
||||||||||||
Pharmaceutical forms |
Concentrate and solvent for solution for infusion
|
||||||||||||
Routes of administration |
Intravenous drip use
|
||||||||||||
Dosage and administration details |
1x100mg
|
||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
overall trial
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Micafungin therapy
|
||
Reporting group description |
PK Parameters from Patients receiving Micafungin were evaluated |
|
|||||||||||
End point title |
Clearance [1] | ||||||||||
End point description |
Pre-/post Hemofilter Clearance
|
||||||||||
End point type |
Primary
|
||||||||||
End point timeframe |
48 hours
|
||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Purely descriptive pharmacokinetic trial, no statistic calculations were performed |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
48 hours
|
||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Adverse events were assessed by chart review
|
||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||
Dictionary version |
10.0
|
||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||
Reporting group title |
whole trial
|
||||||||||||||||||||||||||||||||||
Reporting group description |
all subjects | ||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No Adverse events apart from the two documented SAEs have been found |
|||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
16 Jun 2014 |
Additional sampling at hour 1, 25 and 49 |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/28584142 |